What Nutrients Do You Lose on GLP-1 Medications?

GLP-1 medications are effective at reducing appetite and caloric intake but that effectiveness has a nutritional cost that is often not adequately communicated. When you eat substantially less food, you get substantially less of every nutrient in that food. Here's a specific breakdown of which nutrients are most at risk, why they matter, and what to do about it.

The Fundamental Problem: Eating Less Means Getting Less

Clinical data shows that people on effective doses of semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) typically reduce caloric intake by 2035%. This is the intended effect but it creates a proportional reduction in every micronutrient those calories would have delivered.

The challenge is compounded by food selection changes. When appetite is suppressed, people often reduce protein-rich foods (meat, fish, eggs, dairy) that are also rich in zinc, B12, iron, and calcium. They may reduce vegetable intake when food preparation feels like too much effort. The remaining food calories may skew toward easier-to-eat processed or convenience foods with lower nutritional density.

The result: a population of people eating significantly less, often eating less of the most nutritious foods, at risk of accelerated nutritional deficiency from a medication that is otherwise dramatically improving their metabolic health.

Protein: The Most Consequential Loss

Not strictly a micronutrient, but the most important nutritional consideration on GLP-1 therapy. Inadequate protein during significant caloric restriction leads to muscle loss the body catabolises lean tissue for energy when protein intake is insufficient. Research on GLP-1 medication users found that muscle loss during semaglutide-induced weight loss can be substantially higher than with conventional caloric restriction approaches, largely attributed to insufficient protein intake alongside reduced physical activity.

The consequence: lower resting metabolic rate (muscle burns more calories at rest than fat), reduced strength and functional capacity, and greater difficulty maintaining weight loss after discontinuation.

Target: 1.21.6g of protein per kg body weight daily throughout treatment. High-efficiency sources include: Greek yoghurt (10g protein per 100g), eggs (6g per egg), protein powder supplements, canned fish (20g per 100g), and edamame (11g per 100g).

Iron

Iron deficiency particularly of ferritin (stored iron) is among the most commonly developing deficiencies on GLP-1 therapy. The mechanism is primarily reduced intake of haem iron (from red meat, poultry, and seafood), which is more bioavailable than the non-haem iron in plant foods. Women with already-low iron stores (particularly menstruating women) are at highest risk.

Iron deficiency produces: fatigue, reduced exercise tolerance, brain fog, hair loss, cold sensitivity, and pallor symptoms that may be attributed to the medication or to weight loss itself when iron is the actual cause. Ferritin (not just haemoglobin) should be tested regularly during GLP-1 therapy.

Note: Iron supplementation should only be started if deficiency is confirmed on bloodwork excess iron is harmful. Plant-sourced iron from greens supplements (non-haem iron) is self-limiting in absorption, making it safer from an excess perspective.

Vitamin B12

B12 is found predominantly in animal products meat, fish, dairy, eggs. When intake of these foods decreases significantly (as commonly occurs on GLP-1 therapy where protein foods may be less appealing), B12 intake falls. GLP-1 medications also slow gastric emptying, potentially reducing the gastric acid production needed to release protein-bound B12 from food.

B12 deficiency develops slowly (liver stores last 25 years) but is progressive once it begins. Early symptoms are subtle: mild fatigue, mood changes, slight cognitive dulling. Later symptoms include peripheral neuropathy, megaloblastic anaemia, and more significant cognitive impairment all potentially irreversible if deficiency is prolonged.

Solution: Supplement with methylcobalamin or cyanocobalamin (1000 mcg sublingual or 500 mcg oral daily) free-form B12 that doesn't require gastric acid for absorption, unlike dietary B12.

Calcium and Vitamin D

Reduced dairy intake (common when food intake drops) reduces calcium; reduced outdoor time, reduced fortified food consumption, and GLP-1-related changes in fat-soluble vitamin absorption all contribute to vitamin D risk.

Bone mineral density loss during GLP-1 therapy is a documented concern the mechanical unloading of bone as body weight drops stimulates resorption, and this is compounded by reduced calcium and vitamin D intake. Studies using dual-energy X-ray absorptiometry (DEXA) have found measurable BMD reductions in GLP-1 medication users over 1224 months.

Solution: Vitamin D testing and supplementation to maintain 75125 nmol/L serum 25(OH)D; calcium intake maintained at 10001300mg daily through food and supplementation if dietary intake is inadequate.

Magnesium

Magnesium is chronically under-consumed in the general population; when food intake decreases by 3050%, magnesium shortfall accelerates. The functional consequences muscle cramps, sleep disruption, anxiety, headaches, fatigue are often attributed to the medication when magnesium may be the addressable cause.

Magnesium is found in nuts, seeds, legumes, dark leafy greens, and whole grains foods whose intake frequently declines on GLP-1 therapy. Plant-based greens supplements provide meaningful magnesium and reduce this risk. Supplemental magnesium (magnesium glycinate or citrate, 200400mg elemental) is safe and commonly beneficial.

Zinc

Zinc is found primarily in red meat, shellfish, and legumes. Reduced protein food intake on GLP-1 therapy frequently reduces zinc intake. Zinc deficiency manifests gradually as: reduced immune function (more frequent infections), impaired wound healing, hair thinning, reduced taste and smell acuity, and skin changes. It's rarely the first concern raised by GLP-1 users but is commonly involved in the general immune and energy complaints that develop over months on these medications.

Folate and Other B Vitamins

The B vitamin complex particularly folate, B6, and B1 is found across multiple food categories that may be reduced: whole grains, legumes, leafy greens, meat. B vitamin deficiency contributes to fatigue, mood changes, and cognitive symptoms that compound the physiological changes of significant weight loss. A quality greens supplement provides meaningful B vitamins from plant sources.

The Supplement Strategy

The combination that best protects nutritional status on GLP-1 therapy:

1. High-protein diet prioritised at every meal (1.21.6g/kg/day)
2. Daily greens supplement for plant micronutrients, B vitamins, magnesium, and gut health support
3. Vitamin D (with testing) and calcium as needed
4. B12 (sublingual) for all users significantly reducing animal product intake
5. Magnesium glycinate/citrate (200400mg) if dietary intake is low
6. Iron only if confirmed deficient on blood testing

GRNS covers several of these simultaneously providing plant-sourced B vitamins, magnesium, iron, vitamin K, and prebiotic gut health support in a single daily habit that requires no appetite to maintain.

Frequently Asked Questions

How often should I get bloodwork while on GLP-1 medication?
Discuss with your prescribing doctor. Baseline testing before starting, then every 36 months during active weight loss, is a reasonable framework. Key markers: ferritin, B12, vitamin D, magnesium, calcium, comprehensive metabolic panel, and full blood count.

Does semaglutide itself cause nutrient deficiencies?
The medication's direct pharmacological effects on nutrient absorption are less clear than the indirect effect of reduced food intake. Slowed gastric emptying may affect absorption of some nutrients; fat-soluble vitamin absorption may be altered. But reduced food intake is the primary driver of the deficiencies commonly observed.

Are these nutritional risks unique to semaglutide, or common to all GLP-1 medications?
The mechanisms apply across the GLP-1 class. Tirzepatide (Mounjaro), which adds GIP receptor agonism, produces even greater weight loss and likely similar or greater nutritional risks due to more significant food intake reduction. The principles of nutritional management apply regardless of which specific medication is used.